Stay updated with breaking news from Aadi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
Aadi Bioscience, Inc. (AADI) Wednesday reported loss for the third quarter on higher expenses, wider than the prior year. However, on a per-share basis, loss was narrower than the prior year.
Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 10,338 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $4.32, for a total transaction of $44,660.16. Following the completion of the transaction, the chairman now owns 1,611,205 shares in the […]
Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer LOS ANGELES, Oct. 19,...
Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial...